Scarica l'app Stockscreener
539.73
7.42%
37.26
Dopo l'orario di chiusura:
538.99
-0.74
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Madrigal Pharmaceuticals Q1 2026 Financial Results and Forward-Looking Statements – Rezdiffra Commercialization and Regulatory Updates - Minichart
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals Reports Blockbuster Rezdiffra Sales and Pipeline Expansion in Q1 2026 Financial Results - Minichart
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com
Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Madrigal Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3 - Pharmaceutical Executive
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Madrigal Pharmaceuticals (NASDAQ: MDGL) grows Rezdiffra revenue but remains loss-making - Stock Titan
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth - ChartMill
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore
MADRIGAL PHARMACEUTICALS ($MDGL) Releases Q1 2026 Earnings - Quiver Quantitative
Madrigal: Q1 Earnings Snapshot - KVUE
Madrigal Pharmaceuticals, Inc. announced that its drug interaction study for Ervogastat/Resmetirom is progressing steadily and is expected to officially launch in the fourth quarter of 2026. - Bitget
42,250 patients use Rezdiffra as Madrigal adds MASH gene drug - Stock Titan
Madrigal Pharmaceuticals, Inc. Announces Board Changes, Effective April 22, 2026 - marketscreener.com
Rezdiffra powers Madrigal Pharmaceuticals (NASDAQ: MDGL) to 127% Q1 revenue growth - Stock Titan
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates - ChartMill
Arrowhead and Madrigal sign global licence for MASH RNAi therapy - Yahoo Finance
Madrigal doubles down on MASH with second licensing deal - BioXconomy
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology
Madrigal Expands MASH Franchise With Precision RNAi License For ARO PNPLA3 - simplywall.st
Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors? - Yahoo Finance
Madrigal Pharmaceuticals Q1 2026 earnings preview - MSN
Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH - MedCity News
Madrigal earnings on deck: Can Rezdiffra sustain blockbuster pace? - Investing.com
Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Madrigal Pharmaceuticals Inc announces exclusive global license for Aro-Pnpla3 from Arrowhead - marketscreener.com
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Australia
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline - The Manila Times
After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug - Stock Titan
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
3 Biotech Stocks to Watch for Respectable Growth Beyond AI - AOL.com
(MDGL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
MSN Money - MSN
Madrigal upgraded at Cantor on Rezdiffra launch - MSN
MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $536 - Moomoo
Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial - TipRanks
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Finance Canada
Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
3,876 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Moody Aldrich Partners LLC - MarketBeat
Madrigal to Report Q1 2026 Results May 6, Host Webcast - MyChesCo
Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting - TipRanks
Madrigal Pharmaceuticals | 8-K: Current report - Moomoo
Madrigal Pharmaceuticals (NASDAQ: MDGL) reshapes Board classes ahead of 2026 meeting - Stock Titan
Madrigal Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
[ARS] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Madrigal Pharmaceuticals | DEFA14A: Others - Moomoo
Madrigal Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL) - Seeking Alpha
Madrigal Grants Equity Awards to 12 New Employees - MyChesCo
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. - BioPharma Dive
Pictet Asset Management Holding SA Sells 9,847 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):